Key Highlights
- DataMEDS AI (NASDAQ:MEDS) traded at USD 0.92 intraday on November 13, 2026, up 6.24%, with a Market Value of about USD 4.74 million, near its 52-week low of USD 0.82.
- The company reported a third quarter net operating profit of about USD 10.5 million against a loss of about USD 34.3 million a year earlier, driven mainly by Debt extinguishment and the resolution of litigation liabilities.
- Third quarter Revenue fell to about USD 2.67 million from about USD 3.01 million, and nine month revenue dropped to about USD 6.01 million from about USD 21.67 million.
- The company terminated a planned transaction on November 3, citing market conditions, and is moving into compounded peptide dispensing through its pharmacy unit.
A Profit That Comes From the Balance Sheet
The latest event for DataMEDS AI, formerly Wellgistics Health, is its third quarter report released on November 13, 2026. On the surface the result is strong: a net operating profit of about USD 10.5 million, or USD 2.72 a share on about 3.96 million weighted shares, compared with a loss of about USD 34.3 million a year earlier. The source of that profit matters. It came mainly from gains on extinguishing debt and resolving litigation liabilities, which are one-time items rather than Earnings from selling products. Underlying activity shrank: revenue was about USD 2.67 million against about USD 3.01 million, and nine month revenue of about USD 6.01 million was less than a third of the prior year figure. The nine month net loss was about USD 15.5 million. The stock rose 6.24% to USD 0.92, a modest move for a reported profit of this size, which suggests investors have looked through the one-time gains. Trading of about 1.97 million shares was well below the three-month average of about 6.53 million.
A Strategy in Transition
DataMEDS AI, based in Tampa, Florida, is reshaping itself around pharmacy services and data driven healthcare. In September it acquired Helomics, a Pittsburgh-based business, and in October it licensed a GLP-1 program that remains in force. On November 3, 2026 it terminated an amended letter of intent signed on October 19 for a transaction with a data and technology company, citing market conditions, with no fees owed and no shares to be issued. Its pharmacy unit plans to begin dispensing compounded peptides in November under a federal enforcement discretion policy announced on October 30, starting with six peptides. Compounded products are not approved by the Food and Drug Administration, and the policy that permits this activity could change, so this revenue line carries regulatory risk. DataMEDS AI (NASDAQ:MEDS) regained full compliance with Nasdaq Listing Rules on October 19, 2026, after delisting proceedings began in April.
What Investors Need to Watch
The key question is whether new Business lines can replace the revenue that has fallen away. Peptide dispensing, the GLP-1 license and the Helomics Assets all need time and Capital to scale. The share price, near the bottom of a 52-week range that runs up to USD 35.50, reflects heavy dilution and earlier listing troubles. A price below USD 1.00 also risks a new bid price deficiency notice if it persists for 30 business days, only weeks after compliance was restored. Nasdaq requires at least USD 2.5 million of stockholders' equity, and the gains in the third quarter help on that measure, but further losses would erode it again. Investors should watch fourth quarter revenue and any new financing.
Where Things Stand
DataMEDS AI traded near USD 0.92 on November 13, 2026 after a third quarter profit driven by debt and legal gains rather than operations. Revenue has fallen sharply, and new lines such as compounded peptides carry regulatory risk. Watch the first peptide sales, fourth quarter revenue and any capital raising.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...